Details of the Drug Combination

General Information of Drug Combination (ID: DCPT2GS)

Drug Combination Name
Sorafenib Mitomycin
Indication
Disease Entry Status REF
Non-small cell lung carcinoma Investigative [1]
Component Drugs Sorafenib   DMS8IFC Mitomycin   DMH0ZJE
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: HOP-92
Zero Interaction Potency (ZIP) Score: 1.97
Bliss Independence Score: 4.54
Loewe Additivity Score: 3.98
LHighest Single Agent (HSA) Score: 3.6

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Sorafenib
Disease Entry ICD 11 Status REF
Adenocarcinoma 2D40 Approved [2]
Carcinoma 2A00-2F9Z Approved [2]
Clear cell renal carcinoma N.A. Approved [2]
Lung cancer 2C25.0 Approved [2]
Medullary thyroid gland carcinoma N.A. Approved [2]
Non-small-cell lung cancer 2C25.Y Approved [2]
Renal cell carcinoma 2C90 Approved [3]
Thyroid cancer 2D10 Approved [2]
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Myelodysplastic syndrome 2A37 Phase 2 [3]
Sorafenib Interacts with 4 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Tyrosine-protein kinase Kit (KIT) TTX41N9 KIT_HUMAN Modulator [12]
Platelet-derived growth factor receptor beta (PDGFRB) TTI7421 PGFRB_HUMAN Modulator [12]
Epidermal growth factor receptor (EGFR) TTGKNB4 EGFR_HUMAN Inhibitor [13]
Vascular endothelial growth factor receptor 2 (KDR) TTUTJGQ VGFR2_HUMAN Modulator [12]
------------------------------------------------------------------------------------
Sorafenib Interacts with 7 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [14]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [16]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [17]
Organic cation transporter 1 (SLC22A1) DTT79CX S22A1_HUMAN Substrate [18]
Organic anion transporting polypeptide 1B3 (SLCO1B3) DT9C1TS SO1B3_HUMAN Substrate [17]
RalBP1-associated Eps domain-containing protein 2 (RALBP1) DTYEM9B REPS2_HUMAN Substrate [19]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DTP(s)
Sorafenib Interacts with 6 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [20]
Cytochrome P450 1A2 (CYP1A2) DEJGDUW CP1A2_HUMAN Metabolism [21]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Metabolism [22]
Cytochrome P450 3A7 (CYP3A7) DERD86B CP3A7_HUMAN Metabolism [22]
Cytochrome P450 2C8 (CYP2C8) DES5XRU CP2C8_HUMAN Metabolism [20]
UDP-glucuronosyltransferase 1A9 (UGT1A9) DE85D2P UD19_HUMAN Metabolism [23]
------------------------------------------------------------------------------------
⏷ Show the Full List of 6 DME(s)
Sorafenib Interacts with 112 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2C8 (CYP2C8) OTHCWT42 CP2C8_HUMAN Decreases Activity [24]
ATP-binding cassette sub-family C member 2 (ABCC2) OTJSIGV5 MRP2_HUMAN Affects Response To Substance [25]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Phosphorylation [26]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Expression [27]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [28]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Increases Expression [28]
Bile salt export pump (ABCB11) OTRU7THO ABCBB_HUMAN Decreases Activity [29]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Decreases Activity [30]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Decreases Activity [30]
Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha (PIK3C2A) OTFBU4GD P3C2A_HUMAN Decreases Expression [7]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [7]
Epidermal growth factor receptor (EGFR) OTAPLO1S EGFR_HUMAN Decreases Expression [7]
GTPase NRas (NRAS) OTVQ1DG3 RASN_HUMAN Decreases Expression [7]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Decreases Expression [7]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [7]
Protein kinase C alpha type (PRKCA) OT5UWNRD KPCA_HUMAN Decreases Expression [7]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Expression [7]
Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform (PIK3CA) OTTOMI8J PK3CA_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase mTOR (MTOR) OTHH8KU7 MTOR_HUMAN Decreases Expression [7]
Cyclin-dependent kinase 9 (CDK9) OT2B7OGB CDK9_HUMAN Decreases Expression [7]
Growth factor receptor-bound protein 2 (GRB2) OTOP7LTE GRB2_HUMAN Decreases Expression [7]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [7]
Interferon regulatory factor 5 (IRF5) OT8SIIAP IRF5_HUMAN Increases Expression [7]
Hypoxia-inducible factor 1-alpha (HIF1A) OTADSC03 HIF1A_HUMAN Decreases Expression [7]
Serine/threonine-protein kinase PLK3 (PLK3) OT19CT2Z PLK3_HUMAN Increases Expression [7]
Serine/threonine-protein kinase PLK2 (PLK2) OTKMJXJ8 PLK2_HUMAN Increases Expression [7]
Histone deacetylase 6 (HDAC6) OT9W9MXQ HDAC6_HUMAN Decreases Expression [7]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [28]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [31]
Bcl-2-like protein 11 (BCL2L11) OTNQQWFJ B2L11_HUMAN Decreases Expression [32]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Decreases Expression [8]
E3 ubiquitin-protein ligase parkin (PRKN) OTJBN41W PRKN_HUMAN Increases Ubiquitination [33]
Growth arrest and DNA damage-inducible protein GADD45 beta (GADD45B) OTL9I7LO GA45B_HUMAN Increases Expression [34]
Protein phosphatase 1 regulatory subunit 15A (PPP1R15A) OTYG179K PR15A_HUMAN Increases Expression [9]
Growth arrest and DNA damage-inducible protein GADD45 gamma (GADD45G) OT8V1J4M GA45G_HUMAN Increases Expression [35]
Apoptosis-inducing factor 1, mitochondrial (AIFM1) OTKPWB7Q AIFM1_HUMAN Affects Localization [32]
Tyrosine-protein kinase ABL1 (ABL1) OT09YVXH ABL1_HUMAN Decreases Activity [36]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Decreases Expression [37]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [38]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [39]
RAF proto-oncogene serine/threonine-protein kinase (RAF1) OT51LSFO RAF1_HUMAN Decreases Activity [26]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Expression [40]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [34]
Tyrosine-protein kinase Lck (LCK) OT883FG9 LCK_HUMAN Decreases Phosphorylation [41]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [42]
Eukaryotic translation initiation factor 4E (EIF4E) OTDAWNLA IF4E_HUMAN Decreases Phosphorylation [32]
Proto-oncogene tyrosine-protein kinase receptor Ret (RET) OTLU040A RET_HUMAN Decreases Activity [43]
High mobility group protein B1 (HMGB1) OT4B7CPF HMGB1_HUMAN Increases Expression [39]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [44]
Breakpoint cluster region protein (BCR) OTCN76C1 BCR_HUMAN Decreases Activity [36]
Cytochrome P450 2C9 (CYP2C9) OTGLBN29 CP2C9_HUMAN Decreases Activity [24]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Expression [45]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Increases Expression [8]
Proto-oncogene tyrosine-protein kinase Src (SRC) OTETYX40 SRC_HUMAN Decreases Activity [46]
Serine/threonine-protein kinase B-raf (BRAF) OT7S81XQ BRAF_HUMAN Decreases Activity [47]
Platelet-derived growth factor receptor alpha (PDGFRA) OTDJXUCN PGFRA_HUMAN Decreases Phosphorylation [48]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [28]
Ribosomal protein S6 kinase beta-1 (RPS6KB1) OTAELNGX KS6B1_HUMAN Decreases Phosphorylation [49]
Alanine aminotransferase 1 (GPT) OTOXOA0Q ALAT1_HUMAN Increases Secretion [50]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Expression [51]
G1/S-specific cyclin-D2 (CCND2) OTDULQF9 CCND2_HUMAN Decreases Expression [51]
G1/S-specific cyclin-D3 (CCND3) OTNKPQ22 CCND3_HUMAN Decreases Expression [45]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [52]
Vascular endothelial growth factor receptor 2 (KDR) OT15797V VGFR2_HUMAN Decreases Phosphorylation [26]
Dual specificity mitogen-activated protein kinase kinase 2 (MAP2K2) OTUE7Z91 MP2K2_HUMAN Decreases Phosphorylation [47]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Phosphorylation [53]
Signal transducer and activator of transcription 5A (STAT5A) OTBSJGN3 STA5A_HUMAN Decreases Activity [54]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Decreases Expression [55]
Mitogen-activated protein kinase 8 (MAPK8) OTEREYS5 MK08_HUMAN Decreases Phosphorylation [37]
Mitogen-activated protein kinase 9 (MAPK9) OTCEVJ9E MK09_HUMAN Decreases Phosphorylation [37]
Dual specificity mitogen-activated protein kinase kinase 4 (MAP2K4) OTZPZX11 MP2K4_HUMAN Decreases Phosphorylation [37]
Crk-like protein (CRKL) OTOYSD1R CRKL_HUMAN Decreases Phosphorylation [36]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Expression [56]
CCAAT/enhancer-binding protein delta (CEBPD) OTNBIPMY CEBPD_HUMAN Increases Expression [35]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [55]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Response To Substance [57]
Stanniocalcin-1 (STC1) OTGVVXYF STC1_HUMAN Decreases Expression [58]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [59]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [41]
Gasdermin-D (GSDMD) OTH39BKI GSDMD_HUMAN Increases Expression [39]
Sestrin-2 (SESN2) OT889IXY SESN2_HUMAN Increases Expression [60]
Small ribosomal subunit protein eS6 (RPS6) OTT4D1LN RS6_HUMAN Decreases Phosphorylation [61]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [62]
Cyclin-dependent kinase 6 (CDK6) OTR95N0X CDK6_HUMAN Decreases Expression [45]
Dual specificity mitogen-activated protein kinase kinase 1 (MAP2K1) OT4Y9NQI MP2K1_HUMAN Decreases Phosphorylation [47]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Cleavage [32]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [32]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Activity [63]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [64]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [49]
Eukaryotic translation initiation factor 4E-binding protein 1 (EIF4EBP1) OTHBQVD5 4EBP1_HUMAN Decreases Phosphorylation [65]
Phorbol-12-myristate-13-acetate-induced protein 1 (PMAIP1) OTXEE550 APR_HUMAN Decreases Expression [66]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [10]
Mitogen-activated protein kinase 14 (MAPK14) OT5TCO3O MK14_HUMAN Decreases Expression [67]
Bcl-2 homologous antagonist/killer (BAK1) OTDP6ILW BAK_HUMAN Decreases Expression [32]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [68]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [10]
Docking protein 1 (DOK1) OTGVRLW6 DOK1_HUMAN Decreases Phosphorylation [36]
Serine/threonine-protein kinase PINK1, mitochondrial (PINK1) OT50NR57 PINK1_HUMAN Increases Expression [33]
Eukaryotic translation initiation factor 2A (EIF2A) OTWXELQP EIF2A_HUMAN Increases Phosphorylation [9]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Increases Expression [69]
Transcription factor SOX-17 (SOX17) OT9H4WWE SOX17_HUMAN Decreases Localization [70]
Ubiquitin carboxyl-terminal hydrolase CYLD (CYLD) OT37FKH0 CYLD_HUMAN Increases Expression [27]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [66]
Eukaryotic translation initiation factor 2-alpha kinase 3 (EIF2AK3) OT0DZGY4 E2AK3_HUMAN Increases Phosphorylation [9]
E3 ubiquitin-protein ligase TRIM62 (TRIM62) OT15YO6N TRI62_HUMAN Affects Response To Substance [71]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Response To Substance [32]
ATP-binding cassette sub-family C member 3 (ABCC3) OTC3IJV4 MRP3_HUMAN Affects Response To Substance [25]
Hepatocyte growth factor (HGF) OTGHUA23 HGF_HUMAN Decreases Response To Substance [72]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Affects Response To Substance [25]
Receptor-type tyrosine-protein kinase FLT3 (FLT3) OTMSRYMK FLT3_HUMAN Increases Response To Substance [61]
Na(+)/citrate cotransporter (SLC13A5) OTPH1TA7 S13A5_HUMAN Decreases Response To Substance [73]
------------------------------------------------------------------------------------
⏷ Show the Full List of 112 DOT(s)
Indication(s) of Mitomycin
Disease Entry ICD 11 Status REF
Breast cancer 2C60-2C65 Approved [4]
Gastrointestinal cancer 2C11 Approved [4]
Pancreatic adenocarcinoma N.A. Approved [5]
Solid tumour/cancer 2A00-2F9Z Approved [6]
Urinary bladder cancer N.A. Approved [5]
Urinary bladder neoplasm N.A. Approved [5]
Urinary system neoplasm N.A. Approved [5]
Urinary tract disease GC2Z Approved [5]
Bladder disease DC11-DC1Z Investigative [5]
Colon cancer 2B90.Z Investigative [5]
Mitomycin Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Human Deoxyribonucleic acid (hDNA) TTUTN1I NOUNIPROTAC Binder [80]
------------------------------------------------------------------------------------
Mitomycin Interacts with 1 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [81]
------------------------------------------------------------------------------------
Mitomycin Interacts with 274 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [82]
Alternative prion protein (PRNP) OTE85L1Q APRIO_HUMAN Increases Expression [83]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [83]
HLA class I histocompatibility antigen, C alpha chain (HLA-C) OTV38BUJ HLAC_HUMAN Decreases Expression [83]
Bone morphogenetic protein 4 (BMP4) OTPZMDFH BMP4_HUMAN Decreases Expression [83]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Increases Expression [83]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Increases Expression [83]
Cyclic AMP-dependent transcription factor ATF-4 (ATF4) OTRFV19J ATF4_HUMAN Increases Expression [83]
DNA ligase 1 (LIG1) OTEEQS43 DNLI1_HUMAN Decreases Expression [83]
Nuclear transcription factor Y subunit alpha (NFYA) OTWFFOVH NFYA_HUMAN Increases Expression [83]
Ephrin type-A receptor 2 (EPHA2) OTI6QNX2 EPHA2_HUMAN Decreases Expression [83]
Replication factor C subunit 4 (RFC4) OTWALD2R RFC4_HUMAN Decreases Expression [83]
Matrix metalloproteinase-14 (MMP14) OT9C197Z MMP14_HUMAN Decreases Expression [83]
Activated RNA polymerase II transcriptional coactivator p15 (SUB1) OTK71JYU TCP4_HUMAN Increases Expression [83]
Small ribosomal subunit protein eS1 (RPS3A) OTUEP7CL RS3A_HUMAN Increases Expression [83]
Microtubule-associated protein RP/EB family member 1 (MAPRE1) OTCVQD60 MARE1_HUMAN Increases Expression [83]
Histone-binding protein RBBP7 (RBBP7) OTLB56HX RBBP7_HUMAN Increases Expression [83]
Prostaglandin G/H synthase 2 (PTGS2) OT75U9M4 PGH2_HUMAN Increases Expression [84]
TP53-regulated inhibitor of apoptosis 1 (TRIAP1) OTEAUJXN TRIA1_HUMAN Increases Expression [85]
Superoxide dismutase (SOD1) OT39TA1L SODC_HUMAN Increases Expression [85]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [85]
Heat shock cognate 71 kDa protein (HSPA8) OTJI2RCI HSP7C_HUMAN Increases Expression [85]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Increases Expression [85]
Growth arrest and DNA damage-inducible protein GADD45 alpha (GADD45A) OTDRV63V GA45A_HUMAN Increases Expression [85]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Increases Expression [85]
Quinone oxidoreductase PIG3 (TP53I3) OTSCM68G QORX_HUMAN Increases Expression [85]
DNA damage-binding protein 2 (DDB2) OTO8HVVB DDB2_HUMAN Increases Expression [85]
Cystine/glutamate transporter (SLC7A11) OTKJ6PXW XCT_HUMAN Decreases Expression [86]
Succinate dehydrogenase assembly factor 1, mitochondrial (SDHAF1) OTDG5VW7 SDHF1_HUMAN Decreases Expression [75]
Serine/threonine-protein kinase Sgk1 (SGK1) OT301T1U SGK1_HUMAN Decreases Expression [75]
E3 ubiquitin-protein ligase TRIM38 (TRIM38) OT6SP1M9 TRI38_HUMAN Decreases Expression [75]
Torsin-1A (TOR1A) OTYCLGJU TOR1A_HUMAN Decreases Expression [75]
Telomerase reverse transcriptase (TERT) OT085VVA TERT_HUMAN Decreases Expression [87]
Serine/threonine-protein kinase Chk1 (CHEK1) OTTTI622 CHK1_HUMAN Increases Phosphorylation [88]
Transcription factor EC (TFEC) OTUST8MR TFEC_HUMAN Decreases Expression [75]
Regulator of G-protein signaling 16 (RGS16) OTBKZASI RGS16_HUMAN Decreases Expression [75]
E3 ubiquitin-protein ligase RNF113A (RNF113A) OTR6N7HU R113A_HUMAN Decreases Expression [75]
HMG box-containing protein 1 (HBP1) OTDPGGDV HBP1_HUMAN Decreases Expression [75]
Kinesin-like protein KIF20A (KIF20A) OTXOQHE0 KI20A_HUMAN Decreases Expression [75]
Myelin protein zero-like protein 1 (MPZL1) OTJSUUHR MPZL1_HUMAN Decreases Expression [75]
Serine/threonine-protein kinase Chk2 (CHEK2) OT8ZPCNS CHK2_HUMAN Increases Phosphorylation [88]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [89]
Interleukin-1 alpha (IL1A) OTPSGILV IL1A_HUMAN Increases Expression [90]
Thymidine kinase, cytosolic (TK1) OTY5JFM1 KITH_HUMAN Increases Mutagenesis [91]
Plasminogen activator inhibitor 1 (SERPINE1) OTT0MPQ3 PAI1_HUMAN Increases Expression [90]
Interleukin-6 (IL6) OTUOSCCU IL6_HUMAN Increases Expression [90]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Expression [92]
Fibroblast growth factor 2 (FGF2) OT7YUJ9F FGF2_HUMAN Increases Expression [89]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Activity [93]
Interleukin-8 (CXCL8) OTS7T5VH IL8_HUMAN Increases Expression [94]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Increases Expression [95]
C-C motif chemokine 2 (CCL2) OTAD2HEL CCL2_HUMAN Increases Expression [94]
CD59 glycoprotein (CD59) OTSUMQDH CD59_HUMAN Increases Mutagenesis [96]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [97]
Beta-galactosidase (GLB1) OTB0TKAG BGAL_HUMAN Increases Activity [90]
rRNA 2'-O-methyltransferase fibrillarin (FBL) OTRODIE5 FBRL_HUMAN Affects Localization [98]
Carnitine O-palmitoyltransferase 2, mitochondrial (CPT2) OTIN6G20 CPT2_HUMAN Decreases Expression [75]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [99]
Mitogen-activated protein kinase 3 (MAPK3) OTCYKGKO MK03_HUMAN Increases Phosphorylation [100]
Mitogen-activated protein kinase 1 (MAPK1) OTH85PI5 MK01_HUMAN Increases Phosphorylation [100]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Decreases Expression [75]
RAC-alpha serine/threonine-protein kinase (AKT1) OT8H2YY7 AKT1_HUMAN Decreases Expression [101]
Replication factor C subunit 1 (RFC1) OT3L5PK3 RFC1_HUMAN Decreases Expression [75]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [102]
RNA-binding protein 34 (RBM34) OTX3LUGI RBM34_HUMAN Decreases Expression [75]
Tumor necrosis factor ligand superfamily member 6 (FASLG) OTZARCHH TNFL6_HUMAN Increases Expression [99]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Increases Phosphorylation [90]
LIM/homeobox protein Lhx2 (LHX2) OTK61NP8 LHX2_HUMAN Decreases Expression [75]
DNA mismatch repair protein Msh6 (MSH6) OT46FP09 MSH6_HUMAN Decreases Expression [75]
RecQ-like DNA helicase BLM (BLM) OTEJOAJX BLM_HUMAN Decreases Expression [75]
Ataxin-1 (ATXN1) OTQF0HNR ATX1_HUMAN Decreases Expression [75]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [101]
Ras-related protein Rap-2b (RAP2B) OTD2NDQP RAP2B_HUMAN Decreases Expression [75]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Increases Secretion [102]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Increases Expression [103]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [75]
Transcription factor p65 (RELA) OTUJP9CN TF65_HUMAN Increases Expression [104]
Protein kinase C zeta type (PRKCZ) OTN2FE42 KPCZ_HUMAN Increases Cleavage [102]
DNA repair protein RAD51 homolog 1 (RAD51) OTNVWGC1 RAD51_HUMAN Increases Expression [100]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Decreases Expression [95]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [105]
Tripartite motif-containing protein 26 (TRIM26) OTS0DJIP TRI26_HUMAN Decreases Expression [75]
E3 ubiquitin-protein ligase TRIM32 (TRIM32) OTJOV0PG TRI32_HUMAN Decreases Expression [75]
Chromatin assembly factor 1 subunit A (CHAF1A) OTXSSY4H CAF1A_HUMAN Decreases Expression [75]
Chromatin assembly factor 1 subunit B (CHAF1B) OTOMK4KH CAF1B_HUMAN Decreases Expression [75]
Interleukin-18 (IL18) OTBB2A8O IL18_HUMAN Decreases Expression [104]
Protein BTG3 (BTG3) OT9ANHVT BTG3_HUMAN Decreases Expression [75]
Histone RNA hairpin-binding protein (SLBP) OTVYYQRT SLBP_HUMAN Decreases Expression [75]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [102]
Transforming growth factor-beta-induced protein ig-h3 (TGFBI) OTR443C5 BGH3_HUMAN Decreases Expression [105]
Neutral amino acid transporter B(0) (SLC1A5) OTE2H26Q AAAT_HUMAN Decreases Expression [75]
Protein MCM10 homolog (MCM10) OTV0O3JN MCM10_HUMAN Decreases Expression [75]
Partner and localizer of BRCA2 (PALB2) OT6DNDBG PALB2_HUMAN Decreases Expression [75]
Leucine-rich repeat-containing protein 47 (LRRC47) OTSE8NAO LRC47_HUMAN Decreases Expression [75]
Bcl2-associated agonist of cell death (BAD) OT63ERYM BAD_HUMAN Increases Expression [101]
Cytochrome c oxidase assembly factor 7 (COA7) OTRQJYL6 COA7_HUMAN Decreases Expression [75]
Mitochondrial potassium channel (CCDC51) OTOJNHNA MITOK_HUMAN Decreases Expression [75]
Integrator complex subunit 15 (INTS15) OT3O4INM INT15_HUMAN Decreases Expression [75]
Krueppel-like factor 6 (KLF6) OTQY9S7F KLF6_HUMAN Decreases Expression [75]
Cell division control protein 6 homolog (CDC6) OTX93FE7 CDC6_HUMAN Decreases Expression [75]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [75]
Protein orai-3 (ORAI3) OTUP3OH3 ORAI3_HUMAN Decreases Expression [75]
Protein pelota homolog (PELO) OTF3WLIM PELO_HUMAN Decreases Expression [75]
TIMELESS-interacting protein (TIPIN) OT9PZHXV TIPIN_HUMAN Decreases Expression [75]
Fanconi anemia group D2 protein (FANCD2) OTVEB5LF FACD2_HUMAN Increases Ubiquitination [88]
tRNA pseudouridine(38/39) synthase (PUS3) OT6WG6M2 PUS3_HUMAN Decreases Expression [75]
Transmembrane protein 185B (TMEM185B) OTGNYS0J T185B_HUMAN Decreases Expression [75]
Interferon-stimulated 20 kDa exonuclease-like 2 (ISG20L2) OT3Q11WQ I20L2_HUMAN Decreases Expression [75]
GrpE protein homolog 1, mitochondrial (GRPEL1) OT8O00YJ GRPE1_HUMAN Decreases Expression [75]
Forkhead box protein J2 (FOXJ2) OTPT639J FOXJ2_HUMAN Decreases Expression [75]
Homologous-pairing protein 2 homolog (PSMC3IP) OT9UB5UO HOP2_HUMAN Decreases Expression [75]
rRNA methyltransferase 2, mitochondrial (MRM2) OTRYA1HU MRM2_HUMAN Decreases Expression [75]
Frizzled-1 (FZD1) OTZATHVS FZD1_HUMAN Decreases Expression [75]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Affects Response To Substance [78]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [78]
Acid ceramidase (ASAH1) OT1DNGXL ASAH1_HUMAN Affects Response To Substance [78]
Fanconi-associated nuclease 1 (FAN1) OT1LM1HZ FAN1_HUMAN Increases Response To Substance [106]
Replication factor C subunit 3 (RFC3) OT1MS7AO RFC3_HUMAN Affects Response To Substance [78]
CD9 antigen (CD9) OT2184XU CD9_HUMAN Affects Response To Substance [78]
KN motif and ankyrin repeat domain-containing protein 1 (KANK1) OT2E7A6W KANK1_HUMAN Affects Response To Substance [78]
Aldehyde oxidase (AOX1) OT2FZP6H AOXA_HUMAN Affects Response To Substance [78]
Mitochondrial fission 1 protein (FIS1) OT2HL10J FIS1_HUMAN Affects Response To Substance [78]
Cytoplasmic aconitate hydratase (ACO1) OT2VUR7L ACOHC_HUMAN Affects Response To Substance [78]
Syncytin-2 (ERVFRD-1) OT3064D7 SYCY2_HUMAN Affects Response To Substance [78]
Protein FAM171A1 (FAM171A1) OT33BHEP F1711_HUMAN Affects Response To Substance [78]
Sister chromatid cohesion protein PDS5 homolog A (PDS5A) OT34P56Z PDS5A_HUMAN Affects Response To Substance [78]
Excitatory amino acid transporter 3 (SLC1A1) OT3B9M6W EAA3_HUMAN Affects Response To Substance [78]
Syntabulin (SYBU) OT3FQV7N SYBU_HUMAN Affects Response To Substance [78]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [78]
Prelamin-A/C (LMNA) OT3SG7ZR LMNA_HUMAN Affects Response To Substance [78]
Methylated-DNA--protein-cysteine methyltransferase (MGMT) OT40A9WH MGMT_HUMAN Increases Response To Substance [107]
Pyridoxal kinase (PDXK) OT40AJ5J PDXK_HUMAN Affects Response To Substance [78]
Proteinase-activated receptor 1 (F2R) OT4WVWBO PAR1_HUMAN Affects Response To Substance [78]
Diamine acetyltransferase 1 (SAT1) OT52AU22 SAT1_HUMAN Affects Response To Substance [78]
Breast cancer type 1 susceptibility protein (BRCA1) OT5BN6VH BRCA1_HUMAN Increases Response To Substance [108]
Neprilysin (MME) OT5Q39P8 NEP_HUMAN Affects Response To Substance [78]
Lymphokine-activated killer T-cell-originated protein kinase (PBK) OT5Z27TW TOPK_HUMAN Affects Response To Substance [78]
Protein-glutamine gamma-glutamyltransferase 2 (TGM2) OT6MFOWF TGM2_HUMAN Affects Response To Substance [78]
G-protein-signaling modulator 2 (GPSM2) OT6RPMRM GPSM2_HUMAN Affects Response To Substance [78]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Affects Response To Substance [78]
Interferon-induced GTP-binding protein Mx1 (MX1) OT6X8G5T MX1_HUMAN Increases Response To Substance [109]
Plasminogen activator inhibitor 2 (SERPINB2) OT72QLZB PAI2_HUMAN Affects Response To Substance [78]
Transcriptional regulator ATRX (ATRX) OT77RSQW ATRX_HUMAN Affects Response To Substance [78]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Affects Response To Substance [78]
Ras-related protein Rab-17 (RAB17) OT7NBUGQ RAB17_HUMAN Affects Response To Substance [78]
Stanniocalcin-2 (STC2) OT86YP8G STC2_HUMAN Affects Response To Substance [78]
Pirin (PIR) OT8ALXHU PIR_HUMAN Affects Response To Substance [78]
Myelin proteolipid protein (PLP1) OT8CM9CX MYPR_HUMAN Affects Response To Substance [78]
Protein-S-isoprenylcysteine O-methyltransferase (ICMT) OT8CNKBO ICMT_HUMAN Affects Response To Substance [78]
G0/G1 switch protein 2 (G0S2) OT8FL49L G0S2_HUMAN Affects Response To Substance [78]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit epsilon isoform (PPP2R5E) OT8GPFT5 2A5E_HUMAN Decreases Response To Substance [110]
cAMP-dependent protein kinase inhibitor alpha (PKIA) OT8M5GVO IPKA_HUMAN Affects Response To Substance [78]
Melanoma-associated antigen 12 (MAGEA12) OT8ULELL MAGAC_HUMAN Affects Response To Substance [78]
Serine/threonine-protein phosphatase 2A 55 kDa regulatory subunit B alpha isoform (PPP2R2A) OT9297OG 2ABA_HUMAN Decreases Response To Substance [110]
Tissue factor pathway inhibitor (TFPI) OTA0FX16 TFPI1_HUMAN Affects Response To Substance [78]
Acyl-coenzyme A thioesterase 2, mitochondrial (ACOT2) OTAKUO27 ACOT2_HUMAN Affects Response To Substance [78]
Aldehyde dehydrogenase, dimeric NADP-preferring (ALDH3A1) OTAYZZE6 AL3A1_HUMAN Affects Response To Substance [111]
Long-chain-fatty-acid--CoA ligase 1 (ACSL1) OTB06ESI ACSL1_HUMAN Affects Response To Substance [78]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Affects Response To Substance [78]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [78]
ETS domain-containing protein Elk-3 (ELK3) OTBM9BHT ELK3_HUMAN Affects Response To Substance [78]
High mobility group protein HMGI-C (HMGA2) OTBMBHHL HMGA2_HUMAN Affects Response To Substance [78]
Protein PRRC2C (PRRC2C) OTBX3MXM PRC2C_HUMAN Affects Response To Substance [78]
Melanocyte protein PMEL (PMEL) OTCDDHHM PMEL_HUMAN Affects Response To Substance [78]
BMP and activin membrane-bound inhibitor homolog (BAMBI) OTCEJ8W5 BAMBI_HUMAN Affects Response To Substance [78]
Creatine kinase U-type, mitochondrial (CKMT1A) OTCINHH5 KCRU_HUMAN Affects Response To Substance [78]
Sodium/potassium-transporting ATPase subunit alpha-1 (ATP1A1) OTCJ458Q AT1A1_HUMAN Affects Response To Substance [78]
CD166 antigen (ALCAM) OTCO4LP7 CD166_HUMAN Affects Response To Substance [78]
Cytochrome c oxidase copper chaperone (COX17) OTCP4LH2 COX17_HUMAN Affects Response To Substance [78]
Interleukin-6 receptor subunit alpha (IL6R) OTCQL07Z IL6RA_HUMAN Decreases Response To Substance [112]
Collagen alpha-3(IX) chain (COL9A3) OTCUJOEK CO9A3_HUMAN Affects Response To Substance [78]
A-kinase anchor protein 12 (AKAP12) OTCVRDDX AKA12_HUMAN Affects Response To Substance [78]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Affects Response To Substance [78]
Dickkopf-related protein 3 (DKK3) OTDU94EY DKK3_HUMAN Affects Response To Substance [78]
dTDP-D-glucose 4,6-dehydratase (TGDS) OTEOFLOS TGDS_HUMAN Affects Response To Substance [78]
Calmegin (CLGN) OTEWVFQV CLGN_HUMAN Affects Response To Substance [78]
Ras association domain-containing protein 1 (RASSF1) OTEZIPB7 RASF1_HUMAN Increases Response To Substance [113]
Protocadherin Fat 1 (FAT1) OTF174DH FAT1_HUMAN Affects Response To Substance [78]
Midkine (MDK) OTF24HKC MK_HUMAN Affects Response To Substance [78]
Serine/arginine-rich splicing factor 1 (SRSF1) OTF61HOV SRSF1_HUMAN Affects Response To Substance [78]
Serine/threonine-protein phosphatase 2A 56 kDa regulatory subunit gamma isoform (PPP2R5C) OTF7CGO2 2A5G_HUMAN Increases Response To Substance [110]
G antigen 7 (GAGE7) OTF8BTR9 GAGE7_HUMAN Affects Response To Substance [78]
Serglycin (SRGN) OTFAVSX0 SRGN_HUMAN Affects Response To Substance [78]
Catenin alpha-1 (CTNNA1) OTFC725Z CTNA1_HUMAN Affects Response To Substance [78]
Sortilin (SORT1) OTFCQ4B1 SORT_HUMAN Affects Response To Substance [78]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Affects Response To Substance [78]
Myelin basic protein (MBP) OTFZCEDB MBP_HUMAN Affects Response To Substance [78]
Tudor domain-containing protein 3 (TDRD3) OTG83E2C TDRD3_HUMAN Affects Response To Substance [78]
Enhancer of filamentation 1 (NEDD9) OTGCFN4M CASL_HUMAN Affects Response To Substance [78]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [78]
Multidrug resistance-associated protein 1 (ABCC1) OTGUN89S MRP1_HUMAN Decreases Response To Substance [114]
Sigma intracellular receptor 2 (TMEM97) OTH76ZWK SGMR2_HUMAN Affects Response To Substance [78]
Transmembrane protein 156 (TMEM156) OTH7YJID TM156_HUMAN Affects Response To Substance [78]
Probable JmjC domain-containing histone demethylation protein 2C (JMJD1C) OTHAWK8C JHD2C_HUMAN Affects Response To Substance [78]
Unconventional myosin-X (MYO10) OTHB78ZQ MYO10_HUMAN Affects Response To Substance [78]
Tribbles homolog 2 (TRIB2) OTHSX3MX TRIB2_HUMAN Affects Response To Substance [78]
Actin-binding LIM protein 1 (ABLIM1) OTHXEK3E ABLM1_HUMAN Affects Response To Substance [78]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [78]
Protein S100-A11 (S100A11) OTI57KDN S10AB_HUMAN Affects Response To Substance [78]
Protein S100-A10 (S100A10) OTI71243 S10AA_HUMAN Affects Response To Substance [78]
Melanoma-associated antigen 6 (MAGEA6) OTI8S0O2 MAGA6_HUMAN Affects Response To Substance [78]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Increases Response To Substance [115]
Superoxide dismutase , mitochondrial (SOD2) OTIWXGZ9 SODM_HUMAN Affects Response To Substance [78]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Affects Response To Substance [78]
Protein c-Fos (FOS) OTJBUVWS FOS_HUMAN Affects Response To Substance [78]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Affects Response To Substance [78]
Collagen alpha-2(IV) chain (COL4A2) OTJK1LKN CO4A2_HUMAN Affects Response To Substance [78]
Hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1) OTJQL0I3 HEY1_HUMAN Affects Response To Substance [78]
E3 ubiquitin-protein ligase MYLIP (MYLIP) OTL0PFGV MYLIP_HUMAN Affects Response To Substance [78]
Hematopoietically-expressed homeobox protein HHEX (HHEX) OTLIUVYX HHEX_HUMAN Affects Response To Substance [78]
Glycylpeptide N-tetradecanoyltransferase 2 (NMT2) OTLNA39Z NMT2_HUMAN Affects Response To Substance [78]
Glutathione S-transferase P (GSTP1) OTLP0A0Y GSTP1_HUMAN Increases Response To Substance [116]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Affects Response To Substance [78]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Response To Substance [78]
Bridging integrator 3 (BIN3) OTMIWWDW BIN3_HUMAN Affects Response To Substance [78]
Transcription factor AP-2-alpha (TFAP2A) OTMYT3NK AP2A_HUMAN Affects Response To Substance [78]
Four and a half LIM domains protein 1 (FHL1) OTN535SU FHL1_HUMAN Affects Response To Substance [78]
Cysteine-rich hydrophobic domain-containing protein 2 (CHIC2) OTNE3T6Z CHIC2_HUMAN Affects Response To Substance [78]
Inositol monophosphatase 2 (IMPA2) OTNFB9YN IMPA2_HUMAN Affects Response To Substance [78]
Neural cell adhesion molecule L1 (L1CAM) OTNWAQ4Y L1CAM_HUMAN Affects Response To Substance [78]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Affects Response To Substance [117]
Kynurenine--oxoglutarate transaminase 3 (KYAT3) OTO4U2QK KAT3_HUMAN Affects Response To Substance [78]
Beta-secretase 2 (BACE2) OTO5YQVK BACE2_HUMAN Affects Response To Substance [78]
Histone deacetylase 9 (HDAC9) OTO8O0LF HDAC9_HUMAN Affects Response To Substance [78]
SH3 domain-binding protein 5 (SH3BP5) OTOOEGUJ 3BP5_HUMAN Affects Response To Substance [78]
Glutathione S-transferase Mu 4 (GSTM4) OTOTF8DU GSTM4_HUMAN Affects Response To Substance [78]
Ras-related protein Rab-20 (RAB20) OTP9OOVS RAB20_HUMAN Affects Response To Substance [78]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Affects Response To Substance [78]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [78]
Kazrin (KAZN) OTPM7BYM KAZRN_HUMAN Affects Response To Substance [78]
DNA-binding protein inhibitor ID-4 (ID4) OTPMJ39I ID4_HUMAN Affects Response To Substance [78]
Centrosomal protein of 57 kDa (CEP57) OTPOHLIX CEP57_HUMAN Affects Response To Substance [78]
Epithelial membrane protein 2 (EMP2) OTPS2H0L EMP2_HUMAN Affects Response To Substance [78]
Dermatan-sulfate epimerase (DSE) OTQ108VJ DSE_HUMAN Affects Response To Substance [78]
Adhesion G-protein coupled receptor G1 (ADGRG1) OTQBB8NT AGRG1_HUMAN Affects Response To Substance [78]
Cyclic GMP-AMP phosphodiesterase SMPDL3A (SMPDL3A) OTQDYH8E ASM3A_HUMAN Affects Response To Substance [78]
MAPK/MAK/MRK overlapping kinase (MOK) OTQK7M9V MOK_HUMAN Affects Response To Substance [78]
High mobility group protein HMG-I/HMG-Y (HMGA1) OTQUSHPX HMGA1_HUMAN Affects Response To Substance [78]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Affects Response To Substance [78]
Dr1-associated corepressor (DRAP1) OTRWLF6D NC2A_HUMAN Affects Response To Substance [78]
Latent-transforming growth factor beta-binding protein 2 (LTBP2) OTS88GSD LTBP2_HUMAN Affects Response To Substance [78]
Terminal nucleotidyltransferase 5A (TENT5A) OTSYF511 TET5A_HUMAN Affects Response To Substance [78]
Lipopolysaccharide-induced tumor necrosis factor-alpha factor (LITAF) OTT5JX1F LITAF_HUMAN Affects Response To Substance [78]
DNA repair protein RAD51 homolog 3 (RAD51C) OTUD6SY5 RA51C_HUMAN Increases Response To Substance [118]
Calcium-dependent secretion activator 2 (CADPS2) OTV1FW0M CAPS2_HUMAN Affects Response To Substance [78]
Matrilin-2 (MATN2) OTVDR68G MATN2_HUMAN Affects Response To Substance [78]
NADPH--cytochrome P450 reductase (POR) OTVIDOCH NCPR_HUMAN Increases Response To Substance [116]
Ensconsin (MAP7) OTVSSJ33 MAP7_HUMAN Affects Response To Substance [78]
Protein artemis (DCLRE1C) OTW3KB1I DCR1C_HUMAN Decreases Response To Substance [79]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Affects Response To Substance [78]
Protein mago nashi homolog (MAGOH) OTWRYTOX MGN_HUMAN Affects Response To Substance [78]
Urokinase-type plasminogen activator (PLAU) OTX0QGKK UROK_HUMAN Affects Response To Substance [78]
Acylamino-acid-releasing enzyme (APEH) OTX258QE ACPH_HUMAN Affects Response To Substance [78]
Hematopoietic lineage cell-specific protein (HCLS1) OTX7WGYN HCLS1_HUMAN Affects Response To Substance [78]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Response To Substance [78]
Long-chain fatty acid transport protein 3 (SLC27A3) OTXB60L7 S27A3_HUMAN Affects Response To Substance [78]
Metallothionein-1E (MT1E) OTXJKU4Y MT1E_HUMAN Affects Response To Substance [78]
Arginine vasopressin-induced protein 1 (AVPI1) OTXSBR60 AVPI1_HUMAN Affects Response To Substance [78]
Neuroendocrine protein 7B2 (SCG5) OTXSJMT1 7B2_HUMAN Affects Response To Substance [78]
Carbamoyl-phosphate synthase , mitochondrial (CPS1) OTXV8NSR CPSM_HUMAN Affects Response To Substance [78]
Peripheral myelin protein 22 (PMP22) OTXWYWCZ PMP22_HUMAN Affects Response To Substance [78]
Kinesin-like protein KIF23 (KIF23) OTY850JC KIF23_HUMAN Affects Response To Substance [78]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B) OTY94WRA HM20B_HUMAN Affects Response To Substance [78]
Protein Niban 1 (NIBAN1) OTYOLI12 NIBA1_HUMAN Affects Response To Substance [78]
LIM and calponin homology domains-containing protein 1 (LIMCH1) OTYPC4XA LIMC1_HUMAN Affects Response To Substance [78]
Galectin-3 (LGALS3) OTYQT0ZI LEG3_HUMAN Affects Response To Substance [78]
L-dopachrome tautomerase (DCT) OTYVNTBG TYRP2_HUMAN Affects Response To Substance [78]
Epithelial discoidin domain-containing receptor 1 (DDR1) OTYW1SH8 DDR1_HUMAN Affects Response To Substance [78]
Tissue factor pathway inhibitor 2 (TFPI2) OTZCRWOR TFPI2_HUMAN Affects Response To Substance [78]
Suppressor of tumorigenicity 7 protein (ST7) OTZG8RC6 ST7_HUMAN Affects Response To Substance [78]
NAD(P)H dehydrogenase 1 (NQO1) OTZGGIVK NQO1_HUMAN Increases Response To Substance [116]
CTD small phosphatase-like protein (CTDSPL) OTZJ0CZK CTDSL_HUMAN Affects Response To Substance [78]
C-X-C motif chemokine 5 (CXCL5) OTZOUPCA CXCL5_HUMAN Affects Response To Substance [78]
Eukaryotic translation initiation factor 5B (EIF5B) OTZTT22W IF2P_HUMAN Affects Response To Substance [78]
------------------------------------------------------------------------------------
⏷ Show the Full List of 274 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adenocarcinoma DCQ8RK3 DU-145 Investigative [1]
Large cell lung carcinoma DCSIX1F NCI-H460 Investigative [1]
Lung adenocarcinoma DCRETGN EKVX Investigative [1]
Prostate carcinoma DCSIZTH PC-3 Investigative [1]
Colon adenocarcinoma DCW6RIO COLO 205 Investigative [119]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Sorafenib FDA Label
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5711).
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7089).
5 Mitomycin FDA Label
6 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
7 Novel carbocyclic curcumin analog CUR3d modulates genes involved in multiple apoptosis pathways in human hepatocellular carcinoma cells. Chem Biol Interact. 2015 Dec 5;242:107-22.
8 Destruxin B inhibits hepatocellular carcinoma cell growth through modulation of the Wnt/-catenin signaling pathway and epithelial-mesenchymal transition. Toxicol In Vitro. 2014 Jun;28(4):552-61. doi: 10.1016/j.tiv.2014.01.002. Epub 2014 Jan 13.
9 The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress. Mol Cell Biol. 2007 Aug;27(15):5499-513. doi: 10.1128/MCB.01080-06. Epub 2007 Jun 4.
10 Sorafenib induces apoptosis of AML cells via Bim-mediated activation of the intrinsic apoptotic pathway. Leukemia. 2008 Apr;22(4):808-18. doi: 10.1038/sj.leu.2405098. Epub 2008 Jan 17.
11 Ovatodiolide suppresses yes-associated protein 1-modulated cancer stem cell phenotypes in highly malignant hepatocellular carcinoma and sensitizes cancer cells to chemotherapy in vitro. Toxicol In Vitro. 2018 Sep;51:74-82. doi: 10.1016/j.tiv.2018.04.010. Epub 2018 Apr 24.
12 Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling.Mol Cancer Ther.2008 Oct;7(10):3129-40.
13 Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
14 Multidrug resistance protein 2 implicates anticancer drug-resistance to sorafenib. Biol Pharm Bull. 2011;34(3):433-5.
15 Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation. Mol Cancer Ther. 2010 Feb;9(2):319-26.
16 Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 2011 Apr 4;8(2):571-82.
17 Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. Clin Cancer Res. 2013 Mar 15;19(6):1458-66.
18 Upregulation of histone acetylation reverses organic anion transporter 2 repression and enhances 5-fluorouracil sensitivity in hepatocellular carcinoma
19 Rlip76 transports sunitinib and sorafenib and mediates drug resistance in kidney cancer. Int J Cancer. 2010 Mar 15;126(6):1327-38.
20 Interaction of sorafenib and cytochrome P450 isoenzymes in patients with advanced melanoma: a phase I/II pharmacokinetic interaction study. Cancer Chemother Pharmacol. 2011 Nov;68(5):1111-8.
21 Ontogeny and sorafenib metabolism. Clin Cancer Res. 2012 Oct 15;18(20):5788-95.
22 Drug Interactions Flockhart Table
23 Pharmacokinetic interaction involving sorafenib and the calcium-channel blocker felodipine in a patient with hepatocellular carcinoma. Invest New Drugs. 2011 Dec;29(6):1511-4.
24 Differential inhibition of human CYP2C8 and molecular docking interactions elicited by sorafenib and its major N-oxide metabolite. Chem Biol Interact. 2021 Apr 1;338:109401. doi: 10.1016/j.cbi.2021.109401. Epub 2021 Feb 5.
25 The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS One. 2013 Nov 11;8(11):e78675. doi: 10.1371/journal.pone.0078675. eCollection 2013.
26 Sorafenib induces growth suppression in mouse models of gastrointestinal stromal tumor. Mol Cancer Ther. 2009 Jan;8(1):152-9. doi: 10.1158/1535-7163.MCT-08-0553.
27 Down-regulation of CYLD as a trigger for NF-B activation and a mechanism of apoptotic resistance in hepatocellular carcinoma cells. Int J Oncol. 2011 Jan;38(1):121-31.
28 Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression. Biochem Pharmacol. 2011 Aug 1;82(3):216-26. doi: 10.1016/j.bcp.2011.04.011. Epub 2011 May 13.
29 Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. Toxicol Sci. 2010 Dec; 118(2):485-500.
30 Differential effects of arsenic trioxide on chemosensitization in human hepatic tumor and stellate cell lines. BMC Cancer. 2012 Sep 10;12:402.
31 The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation. Cancer Res. 2007 Oct 1;67(19):9490-500. doi: 10.1158/0008-5472.CAN-07-0598.
32 Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem. 2005 Oct 21;280(42):35217-27. doi: 10.1074/jbc.M506551200. Epub 2005 Aug 18.
33 Sorafenib targets the mitochondrial electron transport chain complexes and ATP synthase to activate the PINK1-Parkin pathway and modulate cellular drug response. J Biol Chem. 2017 Sep 8;292(36):15105-15120. doi: 10.1074/jbc.M117.783175. Epub 2017 Jul 3.
34 Induction of DNA damage-inducible gene GADD45beta contributes to sorafenib-induced apoptosis in hepatocellular carcinoma cells. Cancer Res. 2010 Nov 15;70(22):9309-18. doi: 10.1158/0008-5472.CAN-10-1033. Epub 2010 Nov 9.
35 Growth arrest DNA damage-inducible gene 45 gamma expression as a prognostic and predictive biomarker in hepatocellular carcinoma. Oncotarget. 2015 Sep 29;6(29):27953-65. doi: 10.18632/oncotarget.4446.
36 Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway. Cancer Res. 2009 May 1;69(9):3927-36. doi: 10.1158/0008-5472.CAN-08-2978. Epub 2009 Apr 14.
37 Synergistic antimetastatic effect of cotreatment with licochalcone A and sorafenib on human hepatocellular carcinoma cells through the inactivation of MKK4/JNK and uPA expression. Environ Toxicol. 2018 Dec;33(12):1237-1244. doi: 10.1002/tox.22630. Epub 2018 Sep 6.
38 Sorafenib inhibits transforming growth factor 1-mediated epithelial-mesenchymal transition and apoptosis in mouse hepatocytes. Hepatology. 2011 May;53(5):1708-18. doi: 10.1002/hep.24254.
39 Activation of inflammasomes by tyrosine kinase inhibitors of vascular endothelial growth factor receptor: Implications for VEGFR TKIs-induced immune related adverse events. Toxicol In Vitro. 2021 Mar;71:105063. doi: 10.1016/j.tiv.2020.105063. Epub 2020 Dec 1.
40 Sorafenib is an antagonist of the aryl hydrocarbon receptor. Toxicology. 2022 Mar 30;470:153118. doi: 10.1016/j.tox.2022.153118. Epub 2022 Feb 3.
41 Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1. Leukemia. 2011 May;25(5):838-47. doi: 10.1038/leu.2011.2. Epub 2011 Feb 4.
42 Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007 Oct 1;67(19):9443-54. doi: 10.1158/0008-5472.CAN-07-1473.
43 Sorafenib functions to potently suppress RET tyrosine kinase activity by direct enzymatic inhibition and promoting RET lysosomal degradation independent of proteasomal targeting. J Biol Chem. 2007 Oct 5;282(40):29230-40. doi: 10.1074/jbc.M703461200. Epub 2007 Jul 30.
44 Synergistic activity of letrozole and sorafenib on breast cancer cells. Breast Cancer Res Treat. 2010 Nov;124(1):79-88. doi: 10.1007/s10549-009-0714-5. Epub 2010 Jan 7.
45 Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells. J Pharmacol Exp Ther. 2006 Dec;319(3):1070-80. doi: 10.1124/jpet.106.108621. Epub 2006 Sep 7.
46 Sorafenib induces apoptosis in HL60 cells by inhibiting Src kinase-mediated STAT3 phosphorylation. Anticancer Drugs. 2011 Jan;22(1):79-88. doi: 10.1097/CAD.0b013e32833f44fd.
47 Rap1/B-Raf signaling is activated in neuroendocrine tumors of the digestive tract and Raf kinase inhibition constitutes a putative therapeutic target. Neuroendocrinology. 2007;85(1):45-53. doi: 10.1159/000100508. Epub 2007 Mar 5.
48 Potent activity of ponatinib (AP24534) in models of FLT3-driven acute myeloid leukemia and other hematologic malignancies. Mol Cancer Ther. 2011 Jun;10(6):1028-35. doi: 10.1158/1535-7163.MCT-10-1044. Epub 2011 Apr 11.
49 Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma. Int J Cancer. 2012 Aug 1;131(3):548-57. doi: 10.1002/ijc.26374. Epub 2011 Sep 12.
50 Cytotoxicity of 34 FDA approved small-molecule kinase inhibitors in primary rat and human hepatocytes. Toxicol Lett. 2018 Jul;291:138-148. doi: 10.1016/j.toxlet.2018.04.010. Epub 2018 Apr 12.
51 Sorafenib inhibits signal transducer and activator of transcription 3 signaling associated with growth arrest and apoptosis of medulloblastomas. Mol Cancer Ther. 2008 Nov;7(11):3519-26. doi: 10.1158/1535-7163.MCT-08-0138.
52 Therapeutic targeting of hepatocellular carcinoma cells with antrocinol, a novel, dual-specificity, small-molecule inhibitor of the KRAS and ERK oncogenic signaling pathways. Chem Biol Interact. 2023 Jan 25;370:110329. doi: 10.1016/j.cbi.2022.110329. Epub 2022 Dec 22.
53 Sorafenib derivatives induce apoptosis through inhibition of STAT3 independent of Raf. Eur J Med Chem. 2011 Jul;46(7):2845-51. doi: 10.1016/j.ejmech.2011.04.007. Epub 2011 Apr 14.
54 The multikinase inhibitor sorafenib induces apoptosis in highly imatinib mesylate-resistant bcr/abl+ human leukemia cells in association with signal transducer and activator of transcription 5 inhibition and myeloid cell leukemia-1 down-regulation. Mol Pharmacol. 2007 Sep;72(3):788-95. doi: 10.1124/mol.106.033308. Epub 2007 Jun 26.
55 Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour Biol. 2015 Apr;36(4):2323-34. doi: 10.1007/s13277-014-2839-3. Epub 2014 Nov 22.
56 Proliferation and survival molecules implicated in the inhibition of BRAF pathway in thyroid cancer cells harbouring different genetic mutations. BMC Cancer. 2009 Oct 31;9:387. doi: 10.1186/1471-2407-9-387.
57 The multikinase inhibitor Sorafenib induces apoptosis and sensitises endometrial cancer cells to TRAIL by different mechanisms. Eur J Cancer. 2010 Mar;46(4):836-50. doi: 10.1016/j.ejca.2009.12.025. Epub 2010 Jan 12.
58 Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity. Toxicol Sci. 2015 Feb;143(2):374-84. doi: 10.1093/toxsci/kfu235. Epub 2014 Nov 3.
59 Sorafenib induces preferential apoptotic killing of a drug- and radio-resistant Hep G2 cells through a mitochondria-dependent oxidative stress mechanism. Cancer Biol Ther. 2009 Oct;8(20):1904-13. doi: 10.4161/cbt.8.20.9436. Epub 2009 Oct 6.
60 Protective effect of sestrin2 against iron overload and ferroptosis-induced liver injury. Toxicol Appl Pharmacol. 2019 Sep 15;379:114665. doi: 10.1016/j.taap.2019.114665. Epub 2019 Jul 16.
61 Mechanisms of apoptosis induction by simultaneous inhibition of PI3K and FLT3-ITD in AML cells in the hypoxic bone marrow microenvironment. Cancer Lett. 2013 Feb 1;329(1):45-58. doi: 10.1016/j.canlet.2012.09.020. Epub 2012 Oct 2.
62 The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene. 2005 Oct 20;24(46):6861-9. doi: 10.1038/sj.onc.1208841.
63 Why are most phospholipidosis inducers also hERG blockers?. Arch Toxicol. 2017 Dec;91(12):3885-3895. doi: 10.1007/s00204-017-1995-9. Epub 2017 May 27.
64 The multikinase inhibitor sorafenib induces caspase-dependent apoptosis in PC-3 prostate cancer cells. Asian J Androl. 2010 Jul;12(4):527-34. doi: 10.1038/aja.2010.21. Epub 2010 May 17.
65 Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin. J Transl Med. 2005 Oct 28;3:39. doi: 10.1186/1479-5876-3-39.
66 GSK-3beta inhibition enhances sorafenib-induced apoptosis in melanoma cell lines. J Biol Chem. 2008 Jan 11;283(2):726-32. doi: 10.1074/jbc.M705343200. Epub 2007 Nov 8.
67 Cytotoxic synergy between the multikinase inhibitor sorafenib and the proteasome inhibitor bortezomib in vitro: induction of apoptosis through Akt and c-Jun NH2-terminal kinase pathways. Mol Cancer Ther. 2006 Sep;5(9):2378-87. doi: 10.1158/1535-7163.MCT-06-0235.
68 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
69 Vorinostat and sorafenib increase ER stress, autophagy and apoptosis via ceramide-dependent CD95 and PERK activation. Cancer Biol Ther. 2008 Oct;7(10):1648-62. doi: 10.4161/cbt.7.10.6623. Epub 2008 Oct 12.
70 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
71 TRIM62 silencing represses the proliferation and invasion and increases the chemosensitivity of hepatocellular carcinoma cells by affecting the NF-B pathway. Toxicol Appl Pharmacol. 2022 Jun 15;445:116035. doi: 10.1016/j.taap.2022.116035. Epub 2022 Apr 23.
72 Diospyros kaki leaves inhibit HGF/Met signaling-mediated EMT and stemness features in hepatocellular carcinoma. Food Chem Toxicol. 2020 Aug;142:111475. doi: 10.1016/j.fct.2020.111475. Epub 2020 Jun 6.
73 Comparative proteomic analysis of SLC13A5 knockdown reveals elevated ketogenesis and enhanced cellular toxic response to chemotherapeutic agents in HepG2 cells. Toxicol Appl Pharmacol. 2020 Sep 1;402:115117. doi: 10.1016/j.taap.2020.115117. Epub 2020 Jul 4.
74 Influence of chemotherapeutic agents and cytokines on the expression of 5-fluorouracil-associated enzymes in human colon cancer cell lines. J Gastroenterol. 2006 Feb;41(2):140-50.
75 Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
76 TCDD as a biological response modifier for Mitomycin C: oxygen tension affects enzyme activation, reactive oxygen species and cell death. Life Sci. 2006 Feb 23;78(13):1499-507. doi: 10.1016/j.lfs.2005.07.021. Epub 2005 Oct 14.
77 Expression of X-linked inhibitor of apoptosis protein and its effect on chemotherapeutic sensitivity of bladder carcinoma. J Huazhong Univ Sci Technolog Med Sci. 2007 Jun;27(3):285-7. doi: 10.1007/s11596-007-0317-5.
78 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
79 Differences in sensitivity to DNA-damaging Agents between XRCC4- and Artemis-deficient human cells. J Radiat Res. 2011;52(4):415-24. doi: 10.1269/jrr.10168.
80 Assessment of cell viability, lipid peroxidation and quantification of DNA fragmentation after the treatment of anticancerous drug mitomycin C and ... Exp Toxicol Pathol. 2010 Sep;62(5):503-8.
81 In vivo expansion of MDR1-transduced cells accompanied by a post-transplantation chemotherapy regimen with mitomycin C and methotrexate. J Gene Med. 2010 Jul;12(7):596-603.
82 Mitomycin C induces multidrug resistance in glaucoma surgery. Graefes Arch Clin Exp Ophthalmol. 2008 Feb;246(2):297-304. doi: 10.1007/s00417-007-0695-1. Epub 2007 Oct 13.
83 Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect. 2003 May;111(6):825-35.
84 Apoptosis of human gastric cancer SGC-7901 cells induced by mitomycin combined with sulindac. World J Gastroenterol. 2005 Mar 28;11(12):1829-32.
85 Differential expression of TP53 associated genes in Fanconi anemia cells after mitomycin C and hydroxyurea treatment. Mutat Res. 2008 Oct 30;656(1-2):1-7.
86 Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 2015 Aug 17;28(8):1636-46.
87 Trace levels of mitomycin C disrupt genomic integrity and lead to DNA damage response defect in long-term-cultured human embryonic stem cells. Arch Toxicol. 2015 Jan;89(1):33-45. doi: 10.1007/s00204-014-1250-6. Epub 2014 May 18.
88 Repairing of N-mustard derivative BO-1055 induced DNA damage requires NER, HR, and MGMT-dependent DNA repair mechanisms. Oncotarget. 2015 Sep 22;6(28):25770-83. doi: 10.18632/oncotarget.4514.
89 Effects of mitomycin-C on normal dermal fibroblasts. Laryngoscope. 2006 Apr;116(4):514-7. doi: 10.1097/01.MLG.0000205590.62824.0A.
90 Mitomycin induces alveolar epithelial cell senescence by down-regulating GSK3 signaling. Toxicol Lett. 2021 Nov 1;352:61-69. doi: 10.1016/j.toxlet.2021.09.015. Epub 2021 Oct 5.
91 DNA polymerase kappa protects human cells against MMC-induced genotoxicity through error-free translesion DNA synthesis. Genes Environ. 2017 Jan 7;39:6. doi: 10.1186/s41021-016-0067-3. eCollection 2017.
92 In vitro effect of cyclosporin A, mitomycin C and prednisolone on cell kinetics in cultured human umbilical vein endothelial cells. Thromb Res. 2005;115(3):219-28. doi: 10.1016/j.thromres.2004.09.001.
93 Chloramphenicol-induced mitochondrial stress increases p21 expression and prevents cell apoptosis through a p21-dependent pathway. J Biol Chem. 2005 Jul 15;280(28):26193-9. doi: 10.1074/jbc.M501371200. Epub 2005 May 19.
94 Dexamethasone reduces mitomycin C-related inflammatory cytokine expression without inducing further cell death in corneal fibroblasts. Wound Repair Regen. 2010 Jan-Feb;18(1):59-69. doi: 10.1111/j.1524-475X.2009.00551.x. Epub 2009 Dec 11.
95 The growth-inhibition effect of tamoxifen in the combination chemotherapeutics on the human cholangiocarcinoma cell line QBC939. Mol Biol Rep. 2010 Jul;37(6):2693-701. doi: 10.1007/s11033-009-9801-2. Epub 2009 Sep 13.
96 Comparison of the mutagenic potential of 17 physical and chemical agents analyzed by the flow cytometry mutation assay. Mutat Res. 2006 Dec 1;602(1-2):14-25. doi: 10.1016/j.mrfmmm.2006.07.009. Epub 2006 Oct 11.
97 Development of an integrated assay in human TK6 cells to permit comprehensive genotoxicity analysis in vitro. Mutat Res Genet Toxicol Environ Mutagen. 2020 Jan;849:503129. doi: 10.1016/j.mrgentox.2019.503129. Epub 2019 Dec 27.
98 Specific inhibition of rRNA transcription and dynamic relocation of fibrillarin induced by mercury. Exp Cell Res. 2000 Aug 25;259(1):225-38. doi: 10.1006/excr.2000.4923.
99 Influence of antitumor drugs on the expression of Fas system in SW480 colon cancer cells. Eur J Gastroenterol Hepatol. 2006 Oct;18(10):1071-7. doi: 10.1097/01.meg.0000231750.68513.6c.
100 Curcumin enhances the mitomycin C-induced cytotoxicity via downregulation of MKK1/2-ERK1/2-mediated Rad51 expression in non-small cell lung cancer cells. Toxicol Appl Pharmacol. 2011 Sep 15;255(3):327-38. doi: 10.1016/j.taap.2011.07.012. Epub 2011 Jul 24.
101 Mitomycin-C induces the apoptosis of human Tenon's capsule fibroblast by activation of c-Jun N-terminal kinase 1 and caspase-3 protease. Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3545-52. doi: 10.1167/iovs.04-1358.
102 Mitomycin C induces apoptosis in a caspases-dependent and Fas/CD95-independent manner in human gastric adenocarcinoma cells. Cancer Lett. 2000 Oct 1;158(2):125-32. doi: 10.1016/s0304-3835(00)00489-4.
103 Mdm2 as a sensitive and mechanistically informative marker for genotoxicity induced by benzo[a]pyrene and dibenzo[a,l]pyrene. Toxicol Sci. 2008 Apr;102(2):232-40. doi: 10.1093/toxsci/kfm305. Epub 2007 Dec 20.
104 Mitomycin C induces apoptosis via Fas/FasL dependent pathway and suppression of IL-18 in cervical carcinoma cells. Cancer Lett. 2006 Jun 8;237(1):33-44. doi: 10.1016/j.canlet.2005.05.043. Epub 2005 Jul 12.
105 Mitomycin C induces apoptosis in cultured corneal fibroblasts derived from type II granular corneal dystrophy corneas. Mol Vis. 2008 Jun 30;14:1222-8.
106 FAN1 mutations cause karyomegalic interstitial nephritis, linking chronic kidney failure to defective DNA damage repair. Nat Genet. 2012 Jul 8;44(8):910-5. doi: 10.1038/ng.2347.
107 O(6)-methylguanine DNA-methyltransferase (MGMT) overexpression in melanoma cells induces resistance to nitrosoureas and temozolomide but sensitizes to mitomycin C. Toxicol Appl Pharmacol. 2006 Mar 1;211(2):97-105. doi: 10.1016/j.taap.2005.06.009. Epub 2005 Jul 22.
108 Mutation of the BRCA1 SQ-cluster results in aberrant mitosis, reduced homologous recombination, and a compensatory increase in non-homologous end joining. Oncotarget. 2015 Sep 29;6(29):27674-87. doi: 10.18632/oncotarget.4876.
109 MxA overexpression reveals a common genetic link in four Fanconi anemia complementation groups. J Clin Invest. 1997 Dec 1;100(11):2873-80. doi: 10.1172/JCI119836.
110 PP2A-B56? complex is involved in dephosphorylation of -H2AX in the repair process of CPT-induced DNA double-strand breaks. Toxicology. 2015 May 4;331:57-65. doi: 10.1016/j.tox.2015.03.007. Epub 2015 Mar 12.
111 Human aldehyde dehydrogenase 3A1 inhibits proliferation and promotes survival of human corneal epithelial cells. J Biol Chem. 2005 Jul 29;280(30):27998-8006. doi: 10.1074/jbc.M503698200. Epub 2005 May 19.
112 Sensitization of human renal cell carcinoma cells to cis-diamminedichloroplatinum(II) by anti-interleukin 6 monoclonal antibody or anti-interleukin 6 receptor monoclonal antibody. Cancer Res. 1995 Feb 1;55(3):590-6.
113 Methylation of Ras association domain family protein 1, isoform A correlated with proliferation and drug resistance in hepatocellular carcinoma cell line SMMC-7721. J Gastroenterol Hepatol. 2007 May;22(5):683-9. doi: 10.1111/j.1440-1746.2006.04676.x.
114 [Establishment of MRP-overexpression subline of bladder carcinoma and its MDR phenotype]. Zhonghua Zhong Liu Za Zhi. 2000 Jul;22(4):273-5.
115 Tumor suppressor gene Runx3 sensitizes gastric cancer cells to chemotherapeutic drugs by downregulating Bcl-2, MDR-1 and MRP-1. Int J Cancer. 2005 Aug 10;116(1):155-60. doi: 10.1002/ijc.20919.
116 Concise prediction models of anticancer efficacy of 8 drugs using expression data from 12 selected genes. Int J Cancer. 2004 Sep 10;111(4):617-26. doi: 10.1002/ijc.20289.
117 [Effect of adenovirus-mediated mutant exogenous P27kip1 gene expression on the chemosensitivities of cholangiocarcinoma cell line]. Zhonghua Wai Ke Za Zhi. 2006 Oct 1;44(19):1349-52.
118 Mutation of the RAD51C gene in a Fanconi anemia-like disorder. Nat Genet. 2010 May;42(5):406-9. doi: 10.1038/ng.570. Epub 2010 Apr 18.
119 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.